• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    ARYA Sciences Acquisition Corp III filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    6/8/21 5:11:31 PM ET
    $ARYA
    Business Services
    Finance
    Get the next $ARYA alert in real time by email
    8-K 1 aryaiii-8xk6821.htm 8-K Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549
    FORM 8-K
    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934
    Date of Report (Date of Earliest Event Reported): June 8, 2021
    ARYA SCIENCES ACQUISITION CORP
    III
    (Exact name of registrant as specified in its charter)
    Cayman Islands001-3943498-1541723
    (State or other jurisdiction of incorporation)
    (Commission File Number)
    (I.R.S. Employer Identification No.)
    51 Astor Place, 10th Floor
    New York, NY
    10003
    (Address of principal executive offices)(Zip Code)
    (212) 284-2300
    Registrant’s telephone number, including area code
    Not Applicable
    (Former name or former address, if changed since last report)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
    ☒Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)
    Name of each exchange
    on which registered
    Class A Ordinary Shares, par value $0.0001 per ShareARYA
    The Nasdaq Capital
    Market
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
    Emerging growth company ☒
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 5.07 Submission of Matters to a Vote of Security Holders
    On June 8, 2021, ARYA Sciences Acquisition Corp III (“ARYA”) held an extraordinary general meeting of its shareholders (the “General Meeting”), at which holders of 14,520,657 ordinary shares (consisting of 10,783,157 Class A ordinary shares and 3,737,500 Class B ordinary shares) held of record as of April 1, 2021, the record date for the General Meeting, were present in person or by proxy, representing 75.68% of the voting power of ARYA’s ordinary shares as of the record date for the General Meeting, and constituting a quorum for the transaction of business. The proposals listed below are described in more detail in the definitive proxy statement/prospectus of ARYA, which was filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 14, 2021 (the “Proxy Statement”). A summary of the voting results at the General Meeting is set forth below:
    The shareholders approved the Business Combination Proposal, the Domestication Proposal, the Charter Proposal, each of the Advisory Governing Documents Proposals, the Nasdaq Proposal, the Incentive Award Plan Proposal and the Employee Stock Purchase Plan Proposal (each as defined in the Proxy Statement).
    The voting results for each proposal were as follows:
    The Business Combination Proposal
    ForAgainstAbstain
    14,260,138259,5101,009
    The Domestication Proposal
    ForAgainstAbstain
    14,258,975259,8631,819
    The Charter Proposal
    ForAgainstAbstain
    14,259,527259,3861,744
    Advisory Governing Documents Proposal A
    ForAgainstAbstain
    13,023,9981,490,8785,781
    Advisory Governing Documents Proposal B
    ForAgainstAbstain
    12,332,5502,185,4332,674
    Advisory Governing Documents Proposal C
    ForAgainstAbstain
    12,335,4482,180,7454,464
    Advisory Governing Documents Proposal D
    ForAgainstAbstain
    13,034,0021,484,1562,499



    The Nasdaq Proposal
    ForAgainstAbstain
    14,257,947260,3562,354
    The Incentive Award Proposal
    ForAgainstAbstain
    13,036,5491,480,4413,667
    The Employee Stock Purchase Plan Proposal
    ForAgainstAbstain
    14,251,808265,4543,395
    As there were sufficient votes to approve the above proposals, the “Adjournment Proposal” described in the Proxy Statement was not presented to shareholders.
    Based on the results of the General Meeting, and subject to the satisfaction or waiver of certain other closing conditions as described in the Proxy Statement, the transactions (the “Transactions”) contemplated by that certain Business Combination Agreement (the “Business Combination Agreement”), dated as of February 7, 2021, by and among ARYA, Mako Merger Sub, Inc. and Nautilus Biotechnology, Inc. (“Nautilus”), including the Domestication and the Business Combination (as such terms are defined in the Proxy Statement), are expected to be consummated on June 9, 2021. Following the consummation of the Transactions, the common stock of New Nautilus (as such term is defined in the Proxy Statement) is expected to begin trading on the Nasdaq Capital Market under the symbol “NAUT” on June 10, 2021.
    Additional Information
    ARYA has filed, and the SEC has declared effective, a Registration Statement on Form S-4, containing the Proxy Statement relating to the proposed Business Combination. ARYA has mailed the Proxy Statement and other relevant documents to its shareholders of record. This communication is not a substitute for the Proxy Statement or any other document that ARYA sent or will send to its shareholders in connection with the Business Combination. Investors and security holders of ARYA are advised to read the Proxy Statement in connection with ARYA’s solicitation of proxies for its extraordinary general meeting of shareholders to be held to approve the Business Combination (and related matters) because the Proxy Statement contains important information about the Business Combination and the parties to the Business Combination.  Shareholders are also able to obtain copies of the Proxy Statement, without charge, at the SEC’s website at www.sec.gov or by directing a request to: 51 Astor Place, 10th Floor, New York, New York 10003.
    Participants in the Solicitation
    ARYA, Nautilus and their respective directors, executive officers, other members of management, and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies of ARYA’s shareholders in connection with the Business Combination. A list of the names of those directors and executive officers and a description of their interests in ARYA is contained in the Proxy Statement, which was filed with the SEC and is available free of charge at the SEC's website at www.sec.gov, or by directing a request to: 51 Astor Place, 10th Floor, New York, New York 10003.
    Forward Looking Statements
    Certain statements made herein are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements



    generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters.
    These forward-looking statements include, but are not limited to, statements regarding future events, the Business Combination between ARYA and Nautilus, the estimated or anticipated future results and benefits of the combined company following the Business Combination, including the likelihood and ability of the parties to successfully consummate the Business Combination, future opportunities for the combined company, and other statements that are not historical facts. These statements are based on the current expectations of ARYA’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Arya and Nautilus. These statements are subject to a number of risks and uncertainties regarding ARYA’s businesses and the Business Combination, and actual results may differ materially. These risks and uncertainties include, but are not limited to, general economic, political and business conditions; the inability of the parties to consummate the Business Combination or the occurrence of any event, change or other circumstances that could give rise to the termination of the Business Combination Agreement; the outcome of any legal proceedings that may be instituted against the parties following the announcement of the Business Combination; the receipt of an unsolicited offer from another party for an alternative business transaction that could interfere with the Business Combination; failure to realize the anticipated benefits of the Business Combination, including as a result of a delay in consummating the potential transaction or difficulty in integrating the businesses of ARYA and Nautilus; the risk that the Business Combination disrupts current plans and operations as a result of the announcement and consummation of the Business Combination; the ability of the combined company to grow and manage growth profitably and retain its key employees; the amount of redemption requests made by ARYA’s shareholders; the inability to obtain or maintain the listing of the post-acquisition company’s securities on Nasdaq following the Business Combination; costs related to the Business Combination; and those factors discussed in ARYA’s Proxy Statement relating to the Business Combination or final prospectus relating to its initial public offering, dated August 6, 2020, and other filings with the SEC. There may be additional risks that ARYA presently does not know or that ARYA currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements provide ARYA’s expectations, plans or forecasts of future events and views as of the date of this communication. ARYA anticipates that subsequent events and developments will cause ARYA’s assessments to change. However, while ARYA may elect to update these forward-looking statements at some point in the future, ARYA specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing ARYA’s assessments as of any date subsequent to the date of this communication. Accordingly, undue reliance should not be placed upon the forward-looking statements.
    Disclaimer
    This communication is for informational purposes only and is neither an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy any securities or the solicitation of any vote in any jurisdiction pursuant to the Business Combination or otherwise, nor shall there be any sale, issuance or transfer or securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.



    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    Date: June 8, 2021ARYA SCIENCES ACQUISITION CORP III
       
     By:/s/ Adam Stone
     Name:Adam Stone
     Title:Chief Executive Officer

    Get the next $ARYA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARYA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ARYA
    SEC Filings

    See more
    • SEC Form D filed by ARYA Sciences Acquisition Corp III

      D - Nautilus Biotechnology, Inc. (0001808805) (Filer)

      6/22/21 4:58:45 PM ET
      $ARYA
      Business Services
      Finance
    • ARYA Sciences Acquisition Corp III filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Changes in Registrant’s Certifying Accountant, Financial Statements and Exhibits, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Amendments to the Registrant’s Code of Ethics, or Waiver of a Provision of the Code of Ethics, Change in Shell Company Status, Regulation FD Discl

      8-K - Nautilus Biotechnology, Inc. (0001808805) (Filer)

      6/9/21 8:55:39 PM ET
      $ARYA
      Business Services
      Finance
    • SEC Form 425 filed by ARYA Sciences Acquisition Corp III

      425 - ARYA Sciences Acquisition Corp III (0001808805) (Subject)

      6/8/21 5:13:44 PM ET
      $ARYA
      Business Services
      Finance

    $ARYA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by ARYA Sciences Acquisition Corp III

      SC 13D - Nautilus Biotechnology, Inc. (0001808805) (Subject)

      6/30/21 2:26:38 PM ET
      $ARYA
      Business Services
      Finance
    • SEC Form SC 13D filed by ARYA Sciences Acquisition Corp III

      SC 13D - Nautilus Biotechnology, Inc. (0001808805) (Subject)

      6/21/21 5:00:58 PM ET
      $ARYA
      Business Services
      Finance
    • SEC Form SC 13D filed by ARYA Sciences Acquisition Corp III

      SC 13D - Nautilus Biotechnology, Inc. (0001808805) (Subject)

      6/16/21 5:10:03 PM ET
      $ARYA
      Business Services
      Finance

    $ARYA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MarketBeat Ranks Stocks with Most Insider Buying in June 2021

      SIOUX FALLS, S.D., July 8, 2021 /PRNewswire-PRWeb/ -- MarketBeat, a leading source for stock market data and research tools, has published a monthly list ranking The 10 Stocks with the Most Insider Buying in June 2021. An insider trade occurs when a company executive or individual who has non-public information about a company buys or sells shares of that company's stock. The level of stock that insiders are buying is a potential indicator of the stock's future performance. The MarketBeat editorial team compiled the 10 stocks with the most insider trading by utilizing the company's Stocks with the Most Insider Buying Report. For stocks with the most insider buying, software companies and s

      7/8/21 7:00:00 PM ET
      $UHAL
      $FAII
      $HEC
      $ARYA
      Rental/Leasing Companies
      Consumer Discretionary
      Business Services
      Finance
    • Nautilus Biotechnology Debuts as Publicly Traded Company, Seeks to Deliver on the Untapped Potential of the Human Proteome

      Business combination transaction with Arya Sciences Acquisition Corp III, a special purpose acquisition company sponsored by Perceptive Advisors, closed on June 9, 2021Publicly traded company renamed Nautilus Biotechnology, Inc.Common stock commences trading under ticker symbol “NAUT” on the Nasdaq Global Select Market on June 10, 2021Gross proceeds from this transaction to Nautilus totaled approximately $345 million, combining approximately $145 million of funds held in Arya III’s trust account and a concurrent PIPE financing of $200 million SEATTLE and NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis pla

      6/9/21 10:05:00 PM ET
      $ARYA
      Business Services
      Finance
    • ARYA Sciences Acquisition Corp III Announces Extraordinary General Meeting Teleconference Details

      NEW YORK, June 01, 2021 (GLOBE NEWSWIRE) -- ARYA Sciences Acquisition Corp III ("ARYA") (NASDAQ:ARYA), today announced that, due to the public health and safety concerns related to the coronavirus (COVID-19) pandemic and recommendations and orders from federal and New York authorities, ARYA is strongly encouraging that shareholders attend the extraordinary general meeting of its shareholders on June 8, 2021 at 9:00 a.m., New York City Time (the "General Meeting") remotely by teleconference rather than in person. The purpose of the General Meeting is to vote on certain proposals relating to the previously announced Business Combination Agreement, dated as of February 7, 2021 (the "Business

      6/1/21 5:01:46 PM ET
      $ARYA
      Business Services
      Finance

    $ARYA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: PERCEPTIVE ADVISORS LLC bought $55,070,983 worth of Common Stock (5,507,063 units at $10.00), increasing direct ownership by 1% to 497,038 units

      4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

      6/11/21 5:45:24 PM ET
      $ARYA
      Business Services
      Finance
    • SEC Form 4: ALTMAN MICHAEL SETH converted 4,146,500 units into Common Stock

      4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

      6/11/21 5:32:39 PM ET
      $ARYA
      Business Services
      Finance
    • SEC Form 3 filed by Epperly Melissa B,

      3 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

      6/9/21 9:41:46 PM ET
      $ARYA
      Business Services
      Finance